Kenneth E. Aldridge

1.6k total citations
46 papers, 1.2k citations indexed

About

Kenneth E. Aldridge is a scholar working on Clinical Biochemistry, Molecular Medicine and Pharmacology. According to data from OpenAlex, Kenneth E. Aldridge has authored 46 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Clinical Biochemistry, 16 papers in Molecular Medicine and 14 papers in Pharmacology. Recurrent topics in Kenneth E. Aldridge's work include Bacterial Identification and Susceptibility Testing (31 papers), Antibiotic Resistance in Bacteria (16 papers) and Antibiotics Pharmacokinetics and Efficacy (14 papers). Kenneth E. Aldridge is often cited by papers focused on Bacterial Identification and Susceptibility Testing (31 papers), Antibiotic Resistance in Bacteria (16 papers) and Antibiotics Pharmacokinetics and Efficacy (14 papers). Kenneth E. Aldridge collaborates with scholars based in United States and Saudi Arabia. Kenneth E. Aldridge's co-authors include Charles V. Sanders, Adeel A. Butt, Deborah Ashcraft, David H. Martin, Michael J. Ferris, J. Dennis Fortenberry, Paul L. Fidel, Carl L. Pierson, Stephen G. Jenkins and Jon E. Rosenblatt and has published in prestigious journals such as Clinical Infectious Diseases, The American Journal of Medicine and Journal of Clinical Microbiology.

In The Last Decade

Kenneth E. Aldridge

45 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kenneth E. Aldridge United States 18 348 321 316 240 229 46 1.2k
J. H. Jorgensen United States 18 432 1.2× 220 0.7× 404 1.3× 258 1.1× 183 0.8× 43 1.3k
T.G. Winstanley United Kingdom 13 392 1.1× 248 0.8× 252 0.8× 159 0.7× 89 0.4× 27 1.2k
Stephen D. Allen United States 20 643 1.8× 218 0.7× 471 1.5× 203 0.8× 138 0.6× 53 1.2k
C. Pierson United States 17 430 1.2× 526 1.6× 557 1.8× 132 0.6× 100 0.4× 25 1.2k
E. Yourassowsky Belgium 16 334 1.0× 153 0.5× 333 1.1× 287 1.2× 136 0.6× 170 1.2k
W. Edmund Farrar United States 23 349 1.0× 158 0.5× 280 0.9× 243 1.0× 215 0.9× 78 1.5k
Paul D. Ellner United States 23 371 1.1× 399 1.2× 412 1.3× 116 0.5× 123 0.5× 81 1.3k
Jacqu̧es Acar France 16 358 1.0× 143 0.4× 349 1.1× 142 0.6× 109 0.5× 32 1.0k
Yumi A. Warren United States 25 411 1.2× 475 1.5× 635 2.0× 327 1.4× 119 0.5× 47 1.5k
H.W. Van Landuyt Belgium 21 459 1.3× 202 0.6× 658 2.1× 173 0.7× 83 0.4× 44 1.4k

Countries citing papers authored by Kenneth E. Aldridge

Since Specialization
Citations

This map shows the geographic impact of Kenneth E. Aldridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth E. Aldridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth E. Aldridge more than expected).

Fields of papers citing papers by Kenneth E. Aldridge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth E. Aldridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth E. Aldridge. The network helps show where Kenneth E. Aldridge may publish in the future.

Co-authorship network of co-authors of Kenneth E. Aldridge

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth E. Aldridge. A scholar is included among the top collaborators of Kenneth E. Aldridge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth E. Aldridge. Kenneth E. Aldridge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Aldridge, Kenneth E.. (2002). Ertapenem (MK-0826), a new carbapenem. Diagnostic Microbiology and Infectious Disease. 44(2). 181–186. 20 indexed citations
3.
4.
5.
Aldridge, Kenneth E., Mikhail S. Gelfand, L. Barth Reller, et al.. (1994). A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States. Diagnostic Microbiology and Infectious Disease. 18(4). 235–241. 34 indexed citations
6.
Aldridge, Kenneth E., et al.. (1994). Major methodology-dependent discordant susceptibility results for Bacteroides fragilis group isolates but not other anaerobes. Diagnostic Microbiology and Infectious Disease. 20(3). 135–142. 3 indexed citations
7.
Aldridge, Kenneth E.. (1993). A New Potent β-Lactamase Inhibitor, BRL 42715, with Inherent Activity Against Bacteroides fragilis Group Strains. Clinical Infectious Diseases. 16(Supplement_4). S335–S338. 1 indexed citations
8.
9.
Aldridge, Kenneth E., et al.. (1992). The rapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. Diagnostic Microbiology and Infectious Disease. 15(7). 601–608. 34 indexed citations
10.
Aldridge, Kenneth E.. (1992). In Vitro Susceptibility of Bacteroides fragilis Group Strains from Abscesses, Body Fluids and Wound/Tissue Sources. Clinical Drug Investigation. 4(S1). 1–6. 6 indexed citations
11.
Stratton, Charles W., et al.. (1991). Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group. Diagnostic Microbiology and Infectious Disease. 14(5). 377–382. 7 indexed citations
12.
Sanders, Charles V. & Kenneth E. Aldridge. (1991). Antimicrobial Therapy of Anaerobic Infections, 1991. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 11(2P2). 72S–79S. 5 indexed citations
13.
Aldridge, Kenneth E., et al.. (1990). In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents. Journal of Antimicrobial Chemotherapy. 26(3). 353–359. 4 indexed citations
14.
15.
Aldridge, Kenneth E.. (1989). Comparison of the in vitro action and interaction of cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides spp.. Diagnostic Microbiology and Infectious Disease. 12(1). 45–50. 10 indexed citations
16.
Aldridge, Kenneth E., et al.. (1989). Comparison of the bactericidal activity of cefotaxime and desacetylcefotaxime alone and in combination against Bacteroides fragilis group organisms. Diagnostic Microbiology and Infectious Disease. 12(2). 165–170. 5 indexed citations
17.
Fuchs, Peter, Ronald N. Jones, Arthur L. Barry, et al.. (1988). Effect of clavulanic acid on the susceptibility of clinical anaerobic bacteria to ticarcillin: A multicenter study. Diagnostic Microbiology and Infectious Disease. 9(1). 47–50. 4 indexed citations
18.
Jones, Ronald N., Kenneth E. Aldridge, Arthur L. Barry, et al.. (1988). Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testing. Diagnostic Microbiology and Infectious Disease. 10(4). 221–240. 26 indexed citations
19.
Aldridge, Kenneth E., et al.. (1987). RO23-6240, a new orally absorbed quinolone: In vitro comparison with other broad-spectrum oral antimicrobial agents and imipenem. Diagnostic Microbiology and Infectious Disease. 7(1). 9–19. 7 indexed citations
20.
Aldridge, Kenneth E., et al.. (1978). Comparison of Micro-ID, API 20E, and Conventional Media Systems in Identification of Enterobacteriaceae. Journal of Clinical Microbiology. 7(6). 507–513. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. H. Jorgensen Breakdown of academic impact, for papers by T.G. Winstanley Breakdown of academic impact, for papers by Stephen D. Allen Breakdown of academic impact, for papers by C. Pierson Breakdown of academic impact, for papers by E. Yourassowsky Breakdown of academic impact, for papers by W. Edmund Farrar Breakdown of academic impact, for papers by Paul D. Ellner Breakdown of academic impact, for papers by Jacqu̧es Acar Breakdown of academic impact, for papers by Yumi A. Warren Breakdown of academic impact, for papers by H.W. Van Landuyt
Rankless by CCL
2026